TrialResults-center.org

Menu

Dovitinib multi target TKI

CHIR-258 - CHIR258 - CHIR 258 - dovitinib - TKI-258 - TKI258 - TKI 258

Renal-cell carcinoma (advanced)

All type of patients: 1 trials - GOLD

dovitinib vs sorafenib

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death (overall survival)	no data
progression or death (progression free survival PFS)	0.86 [0.72 1.03]	p=1.00	0	570	1	GOLD,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -